The Epstein–Barr virus and the pathogenesis of lymphoma

Since the discovery in 1964 of the Epstein–Barr virus (EBV) in African Burkitt lymphoma, this virus has been associated with a remarkably diverse range of cancer types. Because EBV persists in the B cells of the asymptomatic host, it can easily be envisaged how it contributes to the development of B‐cell lymphomas. However, EBV is also found in other cancers, including T‐cell/natural killer cell lymphomas and several epithelial malignancies. Explaining the aetiological role of EBV is challenging, partly because the virus probably contributes differently to each tumour and partly because the available disease models cannot adequately recapitulate the subtle variations in the virus–host balance that exist between the different EBV‐associated cancers. A further challenge is to identify the co‐factors involved; because most persistently infected individuals will never develop an EBV‐associated cancer, the virus cannot be working alone. This article will review what is known about the contribution of EBV to lymphoma development. Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  B. Dörken,et al.  Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. , 1997, The Journal of clinical investigation.

[2]  A. Oxenius,et al.  Antigen-Dependent and -Independent Mechanisms of T and B Cell Hyperactivation during Chronic HIV-1 Infection , 2011, Journal of Virology.

[3]  M. Nussenzweig,et al.  Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. , 2012, Blood.

[4]  B. Griffin.  Relation of Burkitt's tumor‐associated herpes‐type virus to infectious mononucleosis , 1998, Reviews in medical virology.

[5]  V. Diehl,et al.  Somatic Mutation of the Cd95 Gene in Human B Cells as a Side-Effect of the Germinal Center Reaction , 2000, The Journal of experimental medicine.

[6]  M. Rowe,et al.  Counteracting Effects of Cellular Notch and Epstein-Barr Virus EBNA2: Implications for Stromal Effects on Virus-Host Interactions , 2014, Journal of Virology.

[7]  M. Wilson,et al.  Spatial clustering of endemic Burkitt's lymphoma in high‐risk regions of Kenya , 2007, International journal of cancer.

[8]  H. Heslop,et al.  Donor T cells to treat EBV-associated lymphoma. , 1994, The New England journal of medicine.

[9]  K. Ohshima,et al.  Senile EBV+ B-Cell Lymphoproliferative Disorders: A Clinicopathologic Study of 22 Patients , 2003, The American journal of surgical pathology.

[10]  G. Klein,et al.  Soluble factors produced by activated CD4+ T cells modulate EBV latency , 2012, Proceedings of the National Academy of Sciences.

[11]  M. Rowe,et al.  Burkitt's lymphoma: The Rosetta Stone deciphering Epstein-Barr virus biology , 2009, Seminars in cancer biology.

[12]  B. Kempkes,et al.  EBNA2 Interferes with the Germinal Center Phenotype by Downregulating BCL6 and TCL1 in Non-Hodgkin's Lymphoma Cells , 2006, Journal of Virology.

[13]  L. Young,et al.  Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells , 1993, The Journal of experimental medicine.

[14]  M. Allday.  How does Epstein–Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma? , 2009, Seminars in cancer biology.

[15]  A. Rickinson,et al.  Epstein–Barr virus–associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2 , 2002, Nature Medicine.

[16]  Robert E. White,et al.  Epigenetic Repression of p16INK4A by Latent Epstein-Barr Virus Requires the Interaction of EBNA3A and EBNA3C with CtBP , 2010, PLoS pathogens.

[17]  E. Jaffe,et al.  The Role of Chemokines in Hodgkin's Disease , 2000, Leukemia & lymphoma.

[18]  A. Rickinson.  Co-infections, inflammation and oncogenesis: future directions for EBV research. , 2014, Seminars in cancer biology.

[19]  S. Monti,et al.  The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma , 2007, Proceedings of the National Academy of Sciences.

[20]  Paloma Martin,et al.  Epstein–Barr virus in the germinal centres of adenopathies affected by classic Hodgkin lymphoma , 2011, Histopathology.

[21]  A. Fauci,et al.  Insights into B cells and HIV‐specific B‐cell responses in HIV‐infected individuals , 2013, Immunological reviews.

[22]  V. Gattei,et al.  Interactions Between Tissue Fibroblasts in Lymph Nodes and Hodgkin/Reed-Sternberg Cells , 2004, Leukemia & lymphoma.

[23]  A. Carbone,et al.  Expression of CCR5 receptors on Reed–Sternberg cells and Hodgkin lymphoma cell lines: Involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions , 2008, International journal of cancer.

[24]  R. Küppers.  New insights in the biology of Hodgkin lymphoma. , 2012, Hematology. American Society of Hematology. Education Program.

[25]  G. Klein.  Specific chromosomal translocations and the genesis of B-cell-derived tumors in mice and men , 1983, Cell.

[26]  D. Thorley-Lawson,et al.  The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. , 2000, Immunity.

[27]  T. Naoe,et al.  Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients , 2007, Clinical Cancer Research.

[28]  R. Gascoyne,et al.  Newly identified mechanisms in B-cell non-Hodgkin lymphomas uncovered by next-generation sequencing. , 2013, Seminars in hematology.

[29]  U. Klein,et al.  Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  O. Martínez-Maza,et al.  Infection of human B cells with Epstein-Barr virus results in the expression of somatic hypermutation-inducing molecules and in the accrual of oncogene mutations. , 2007, Molecular immunology.

[31]  H. Heslop,et al.  T-cell therapy in the treatment of post-transplant lymphoproliferative disease , 2012, Nature Reviews Clinical Oncology.

[32]  V. Diehl,et al.  Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. , 1968, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Moormann,et al.  Microgeographic variations in Burkitt's lymphoma incidence correlate with differences in malnutrition, malaria and Epstein–Barr virus , 2010, British Journal of Cancer.

[34]  H. Anton-Culver,et al.  Changes in acquired immunodeficiency syndrome‐related non‐Hodgkin lymphoma in the era of highly active antiretroviral therapy , 2006, Cancer.

[35]  K. Duca,et al.  Epstein-Barr virus: a paradigm for persistent infection - for real and in virtual reality. , 2008, Trends in immunology.

[36]  R. Küppers,et al.  Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma , 2006, International journal of cancer.

[37]  W. Henle,et al.  Antibody coating and agglutination of virus particles separated from the EB3 line of Burkitt lymphoma cells , 1966, Journal of bacteriology.

[38]  L. Young,et al.  Immunohistochemical demonstration of the Epstein–Barr virus‐encoded latent membrane protein in paraffin sections of Hodgkin's disease , 1992, The Journal of pathology.

[39]  R. Khanna,et al.  Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. , 2007, Blood.

[40]  M. Rowe,et al.  Epstein-Barr Virus and the Pathogenesis of T and NK Lymphoma: a Mystery Unsolved , 2012, Current Hematologic Malignancy Reports.

[41]  T. Zander,et al.  RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4+ T cells in Hodgkin lymphoma. , 2007, Blood.

[42]  G. Sonenshein,et al.  Transcriptional activation of immunoglobulin α heavy-chain genes by translocation of the c-myc oncogene , 1983, Nature.

[43]  D. Calado,et al.  Germinal Centers , 2017, Methods in Molecular Biology.

[44]  S. Pileri,et al.  Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. , 2005, Blood.

[45]  K. Rajewsky,et al.  Epstein–Barr virus-infected B cells expanding in germinal centers of infectious mononucleosis patients do not participate in the germinal center reaction , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  R. Krance,et al.  Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation , 1995, The Lancet.

[47]  D. Thorley-Lawson,et al.  Epstein-Barr virus: exploiting the immune system , 2001, Nature Reviews Immunology.

[48]  G. Lenz,et al.  The molecular biology of diffuse large B-cell lymphoma , 2011, Therapeutic advances in hematology.

[49]  Katherine Luzuriaga,et al.  Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[50]  I. Ernberg,et al.  Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells. , 2008, The American journal of pathology.

[51]  L. Young,et al.  Differences in B cell growth phenotype reflect novel patterns of Epstein‐Barr virus latent gene expression in Burkitt's lymphoma cells. , 1987, The EMBO journal.

[52]  G. Nilsson,et al.  The potential role of innate immunity in the pathogenesis of Hodgkin's lymphoma. , 2007, Hematology/oncology clinics of North America.

[53]  H. Stein,et al.  Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue. , 1992, Blood.

[54]  Paloma Martin,et al.  Evidence of the intersection of Epstein‐Barr virus with germinal center , 2012, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[55]  Andrew I. Bell,et al.  An Epstein-Barr Virus Anti-Apoptotic Protein Constitutively Expressed in Transformed Cells and Implicated in Burkitt Lymphomagenesis: The Wp/BHRF1 Link , 2009, PLoS pathogens.

[56]  L. Gu,et al.  Transforming growth factor beta 1 messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin's disease. , 1995, Journal of clinical pathology.

[57]  S. Parkes,et al.  South Asian ethnicity and material deprivation increase the risk of Epstein-Barr virus infection in childhood Hodgkin's disease , 2001, British Journal of Cancer.

[58]  L. Pantanowitz,et al.  AIDS-related non-Hodgkin lymphoma: still a problem in the era of HAART. , 2004, The AIDS reader.

[59]  M. Gulley,et al.  Population‐based patterns of human immunodeficiency virus‐related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988–1998 , 2003, Cancer.

[60]  C. Copie-Bergman,et al.  Epstein‐Barr virus in B‐cell lymphomas associated with chronic suppurative inflamation , 1997, The Journal of pathology.

[61]  D. Thorley-Lawson,et al.  The Intersection of Epstein-Barr Virus with the Germinal Center , 2009, Journal of Virology.

[62]  V. Diehl,et al.  STAT3 is constitutively activated in Hodgkin cell lines. , 2001, Blood.

[63]  P. Brousset,et al.  Epstein‐Barr virus‐associated Hodgkin's disease: Epidemiologic characteristics in international data , 1997, International journal of cancer.

[64]  D. McCance.  Pathological Society of Great Britain and Ireland , 1984 .

[65]  A. Carbone,et al.  Lymphomas occurring specifically in HIV-infected patients: from pathogenesis to pathology. , 2013, Seminars in cancer biology.

[66]  O. Kirk,et al.  Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. , 2001, Blood.

[67]  M. Wahlgren,et al.  A Molecular Link between Malaria and Epstein–Barr Virus Reactivation , 2007, PLoS pathogens.

[68]  T. Mak,et al.  The role of cytokines in classical Hodgkin lymphoma. , 2002, Blood.

[69]  M. Wilson,et al.  Spatial distribution of Burkitt’s lymphoma in Kenya and association with malaria risk , 2007, Tropical medicine & international health : TM & IH.

[70]  R. Barker,et al.  Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. , 2004, Blood.

[71]  K. Young,et al.  EBV-positive diffuse large B-cell lymphoma of the elderly. , 2013, Blood.

[72]  N. Probst-Hensch,et al.  Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy , 2008, AIDS.

[73]  K. Takada,et al.  Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV , 1994, Journal of virology.

[74]  U. Storb,et al.  Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. , 1998, Science.

[75]  C. Woodman,et al.  Role of Sexual Behavior in the Acquisition of Asymptomatic Epstein-Barr Virus Infection: A Longitudinal Study , 2005, The Pediatric infectious disease journal.

[76]  W. Klapper,et al.  Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. , 2012, Blood.

[77]  R. Küppers,et al.  Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. , 2005, Blood.

[78]  D. Rossi,et al.  Post‐transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis , 2005, Hematological oncology.

[79]  Riccardo Dalla-Favera,et al.  Germinal centres: role in B-cell physiology and malignancy , 2008, Nature Reviews Immunology.

[80]  H. Herbst,et al.  EPSTEIN–BARR VIRUS (EBV) INFECTION IN INFECTIOUS MONONUCLEOSIS: VIRUS LATENCY, REPLICATION AND PHENOTYPE OF EBV‐INFECTED CELLS , 1997, The Journal of pathology.

[81]  E. Jaffe,et al.  Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. , 2011, Blood.

[82]  P. Smith,et al.  Type IV collagen in Hodgkin's disease. An immunohistochemical study. , 1988, American journal of clinical pathology.

[83]  W. Blattner,et al.  Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. , 1997, International journal of cancer.

[84]  G. Bornkamm,et al.  Burkitt lymphoma: the role of Epstein‐Barr virus revisited , 2012, British journal of haematology.

[85]  D. Thorley-Lawson,et al.  Terminal Differentiation into Plasma Cells Initiates the Replicative Cycle of Epstein-Barr Virus In Vivo , 2005, Journal of Virology.

[86]  A. Mottok,et al.  Epstein‐Barr virus (EBV)‐positive lymphoproliferations in post‐transplant patients show immunoglobulin V gene mutation patterns suggesting interference of EBV with normal B cell differentiation processes , 2003, European journal of immunology.

[87]  A. Rickinson,et al.  Three restricted forms of Epstein–Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells , 2006, Proceedings of the National Academy of Sciences.

[88]  M. Fukayama,et al.  Epstein-Barr virus in pyothorax-associated pleural lymphoma. , 1993, The American journal of pathology.

[89]  L. Pasqualucci,et al.  BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[90]  B. Jungnickel,et al.  Rescue of "crippled" germinal center B cells from apoptosis by Epstein-Barr virus. , 2005, Blood.

[91]  J. Kutok,et al.  B cell receptor signal strength determines B cell fate , 2004, Nature Immunology.

[92]  S. Frost,et al.  Germinal centre destruction as a major pathway of HIV pathogenesis. , 1994, Journal of acquired immune deficiency syndromes.

[93]  G. Klein,et al.  Characteristic chromosomal abnormalities in biopsies and lymphoid‐cell lines from patients with burkitt and non‐burkitt lymphomas , 1976, International journal of cancer.

[94]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[95]  S. Anderson,et al.  Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. , 1998, Immunity.

[96]  M. Narbaitz,et al.  Epstein–Barr virus presence in pediatric diffuse large B‐cell lymphoma reveals a particular association and latency patterns: Analysis of viral role in tumor microenvironment , 2013, International journal of cancer.

[97]  A. Rickinson,et al.  Epstein-Barr Virus Infection of Naïve B Cells In Vitro Frequently Selects Clones with Mutated Immunoglobulin Genotypes: Implications for Virus Biology , 2012, PLoS pathogens.

[98]  Mitchell Cohen,et al.  Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma association is not only restricted to elderly patients , 2014, International journal of cancer.

[99]  S. Tangye,et al.  Epstein-Barr virus persistence in the absence of conventional memory B cells: IgM+IgD+CD27+ B cells harbor the virus in X-linked lymphoproliferative disease patients. , 2008, Blood.

[100]  M. Rowe,et al.  Quantitative Studies of Epstein-Barr Virus-Encoded MicroRNAs Provide Novel Insights into Their Regulation , 2010, Journal of Virology.

[101]  G. Remuzzi,et al.  Lymphomas occurring late after solid-organ transplantation: Influence of treatment on the clinical outcome , 2002, Transplantation.

[102]  W. Hammerschmidt,et al.  Epstein-Barr Virus Nuclear Antigen 2 (EBNA2) Gene Deletion Is Consistently Linked with EBNA3A, -3B, and -3C Expression in Burkitt's Lymphoma Cells and with Increased Resistance to Apoptosis , 2005, Journal of Virology.

[103]  G. Manolov,et al.  Marker Band in One Chromosome 14 from Burkitt Lymphomas , 1972, Nature.

[104]  D. Thorley-Lawson,et al.  Persistence of the Epstein-Barr virus and the origins of associated lymphomas. , 2004, The New England journal of medicine.

[105]  G. Nilsson,et al.  Expression of CCL5/RANTES by Hodgkin and Reed‐Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue , 2003, International journal of cancer.

[106]  R Fischer,et al.  Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[107]  D. Schatz,et al.  Two levels of protection for the B cell genome during somatic hypermutation , 2008, Nature.

[108]  H. Stein,et al.  Frequent expansion of Epstein–Barr virus (EBV) infected cells in germinal centres of tonsils from an area with a high incidence of EBV‐associated lymphoma , 1999, The Journal of pathology.

[109]  B. Stollar,et al.  Influence of EBV on the Peripheral Blood Memory B Cell Compartment1 , 2007, The Journal of Immunology.

[110]  S. Tracy,et al.  The pathogenesis of Epstein-Barr virus persistent infection. , 2013, Current opinion in virology.

[111]  K. Sugimoto,et al.  Epstein-Barr Virus Infection of Human Natural Killer Cell Lines and Peripheral Blood Natural Killer Cells , 2004, Cancer Research.

[112]  L. Young,et al.  Constitutive activation of phosphatidyl‐inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR , 2005, The Journal of pathology.

[113]  H. Stein,et al.  Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. , 1999, Blood.

[114]  Celina G. Kleer,et al.  Discoidin domain receptor tyrosine kinases: new players in cancer progression , 2012, Cancer and Metastasis Reviews.

[115]  T. Wu,et al.  Detection of ebv gene expression in reed‐sternberg cells of Hodgkin's disease , 1990, International journal of cancer.

[116]  E. Cesarman,et al.  Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. , 2007, Blood.

[117]  F. Alexander,et al.  Detection of Epstein-Barr virus genomes in Hodgkin's disease: relation to age. , 1991, Journal of clinical pathology.

[118]  J. Goedert,et al.  HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. , 2011, Blood.

[119]  D. Wright,et al.  Epstein–Barr virus and Hodgkin’s disease: further evidence for the three disease hypothesis , 1998, Leukemia.

[120]  Robert E. White,et al.  EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. , 2012, The Journal of clinical investigation.

[121]  Robert E. White,et al.  Two Epstein–Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma , 2008, Oncogene.

[122]  E. Cesarman,et al.  HIV-associated lymphomas and gamma-herpesviruses. , 2009, Blood.

[123]  S. Kato,et al.  Epstein-Barr virus-associated natural killer/T-cell lymphomas. , 2013, Best practice & research. Clinical haematology.

[124]  G. Kollias,et al.  Comparative Analysis of Signal Transduction by CD40 and the Epstein-Barr Virus Oncoprotein LMP1 In Vivo , 2004, Journal of Virology.

[125]  J. Goedert,et al.  Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. , 2006, Blood.

[126]  K. Rajewsky,et al.  LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1. , 2008, Blood.

[127]  M. Ueffing,et al.  Latent membrane protein 1 of Epstein–Barr virus mimics a constitutively active receptor molecule , 1997, The EMBO journal.

[128]  W. Blattner,et al.  Non‐Hodgkin's lymphoma among people with AIDS: Incidence, presentation and public health burden , 1997 .

[129]  B. Sugden,et al.  Epstein-Barr virus provides a survival factor to Burkitt's lymphomas , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[130]  J. H. Pope,et al.  Transformation of foetal human leukocytes in vitro by filtrates of a human leukaemic cell line containing herpes‐like virus , 1968 .

[131]  P. Casali,et al.  EBV-Encoded Latent Membrane Protein 1 Cooperates with BAFF/BLyS and APRIL to Induce T Cell-Independent Ig Heavy Chain Class Switching 1 , 2003, The Journal of Immunology.

[132]  G. Bornkamm.  Epstein-Barr virus and its role in the pathogenesis of Burkitt's lymphoma: an unresolved issue. , 2009, Seminars in cancer biology.

[133]  A. Carbone,et al.  CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. , 1995, The American journal of pathology.

[134]  R. Longnecker,et al.  Epstein-Barr Virus LMP2A Alters In Vivo and In Vitro Models of B-Cell Anergy, but Not Deletion, in Response to Autoantigen , 2005, Journal of Virology.

[135]  S. Rosati,et al.  Epstein-Barr virus, the germinal centre and the development of Hodgkin's lymphoma. , 2014, The Journal of general virology.

[136]  M. Pawlita,et al.  Epstein‐Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c‐myc gene in Burkitt's lymphoma cells. , 1996, The EMBO journal.

[137]  R. Yamamoto,et al.  PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. , 2007, Blood.

[138]  K. Rajewsky,et al.  EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. , 2000, Immunity.

[139]  A. Polack,et al.  Antagonistic effects of c‐myc and Epstein‐Barr virus latent genes on the phenotype of human B cells , 2001, International journal of cancer.

[140]  A. van den Berg,et al.  Immune reactions in classical Hodgkin's lymphoma. , 1999, Seminars in hematology.

[141]  D. Thorley-Lawson,et al.  Germinal Center B Cells Latently Infected with Epstein-Barr Virus Proliferate Extensively but Do Not Increase in Number , 2009, Journal of Virology.

[142]  K. Rajewsky,et al.  Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells , 1996, The Journal of experimental medicine.

[143]  L. Young,et al.  Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. , 1998, Blood.

[144]  S. Pittaluga,et al.  Selective generation of functional somatically mutated IgM+CD27+, but not Ig isotype-switched, memory B cells in X-linked lymphoproliferative disease. , 2006, The Journal of clinical investigation.

[145]  C. Copie-Bergman,et al.  Epstein-Barr virus in B-cell lymphomas associated with chronic suppurative inflammation. , 1997, The Journal of pathology.

[146]  J. Gordon,et al.  The Epstein–Barr virus oncoprotein, latent membrane protein‐1, reprograms germinal centre B cells towards a Hodgkin's Reed–Sternberg‐like phenotype , 2008, The Journal of pathology.

[147]  G. Klein,et al.  IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter , 2009, Proceedings of the National Academy of Sciences.

[148]  P. Murray,et al.  Suppression of the LMP2A target gene, EGR‐1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle , 2013, The Journal of pathology.

[149]  M. Drayson,et al.  Epstein-Barr virus infection in vitro can rescue germinal center B cells with inactivated immunoglobulin genes. , 2005, Blood.

[150]  A. Webster,et al.  Post-transplant lymphoproliferative disorders , 2016, Nature Reviews Disease Primers.

[151]  C. Gregory,et al.  Apoptosis in Burkitt lymphoma cells is driven by c-myc. , 1993, Oncogene.

[152]  B. Kempkes,et al.  c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[153]  P. Kearns,et al.  The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagen-mediated activation of DDR1. , 2013, Blood.

[154]  A. Moormann,et al.  The company malaria keeps: how co-infection with Epstein–Barr virus leads to endemic Burkitt lymphoma , 2011, Current opinion in infectious diseases.

[155]  B. Jungnickel,et al.  Epstein-Barr virus nuclear antigen 2 inhibits AID expression during EBV-driven B-cell growth. , 2006, Blood.

[156]  M. Shipp,et al.  PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies , 2013, Clinical Cancer Research.

[157]  E. Kieff,et al.  Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression , 2011, Proceedings of the National Academy of Sciences.

[158]  C. Leow,et al.  Malaria drives T cells to exhaustion , 2014, Front. Microbiol..

[159]  H. Ochs,et al.  Absence of IgD-CD27(+) memory B cell population in X-linked hyper-IgM syndrome. , 1998, The Journal of clinical investigation.

[160]  A. Chott,et al.  Epstein–Barr virus is present in neoplastic cytotoxic T cells in extranodal, and predominantly in B cells in nodal T non‐Hodgkin lymphomas , 2000, The Journal of pathology.